… to anti-epidermal growth factor receptor (EGFR) monoclonal … In this phase 1b multicenter,
open-label, dose-finding study (… phase 2 dose of 400 mg that had previously been selected in …

… A triplet combination of epidermal growth factor receptor (EGFR) monoclonal antibody and
… The dose-escalation portion of the study determined the recommended phase II dose (RP2D…

… the addition of the epidermal growth factor receptor (EGFR) antibody cetuximab to a cisplatin
… The RESGEX study was a phase II, randomized, controlled, open-label, multicenter study of …

… This study hypothesized that dual blockade of mammalian target of rapamycin and epidermal
growth factor receptor (… In this multicenter, randomized clinical study, patients with recurrent/…

… Epidermal growth factor receptor (EGFR) inhibitors are … Anti-EGFR monoclonal antibodies
(MoAbs), such as cetuximab or … VELO is a multicenter randomized phase II trial which is …

… conducted a phase II multi-institutional clinical trial to determine … treated with a combination
of cetuximab and nivolumab. In … Open-label, uncontrolled, multicenter phase II study to …

… were enrolled in this phase II, multicenter trial and randomly assigned to receive afatinib
40 mg orally daily plus cetuximab 500 mg/m 2 intravenously every 2 weeks or afatinib alone. …

… [15] demonstrated that adding cetuximab to CCRT did not improve outcome for stage III to IV
… So, we designed a single-arm, open-label phase II clinical trial investigating the efficacy and …

… from the anti-epidermal growth factor receptor (EGFR) antibody treatment. The purpose of
this study was to examine the efficacy and safety of biweekly cetuximab plus mFOLFOX6 or …

… Anti-epidermal growth factor receptor (EGFR) monoclonal … -arm, multi-center phase II study
of cetuximab plus avelumab … with cetuximab (400 mg/m 2 and, subsequently, 250 mg/m 2 …